ROBYN CRISP: Open Payments
NPI 1144705922 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 15 payments from 12 companies in 2025. Trend: 2023 $523 · 2024 $186 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 1 | $135 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $109 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Genentech USA, Inc. | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Legend Biotech USA Inc. | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Merck Sharp & Dohme LLC | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
Products named: RYBREVANT, Nubeqa, Vanflyta, CARVYKTI, Onivyde, KEYTRUDA, Venclexta, REVUFORJ.
Industry payments across DE — which companies pay providers there.
